Shares of Diplomat Pharmacy Inc (NYSE:DPLO) dropped 10.4% during mid-day trading on Friday . The company traded as low as $22.21 and last traded at $22.33. Approximately 3,371,300 shares traded hands during mid-day trading, an increase of 267% from the average daily volume of 918,233 shares. The stock had previously closed at $24.93.
DPLO has been the subject of a number of recent analyst reports. Zacks Investment Research cut Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research report on Tuesday, May 1st. ValuEngine cut Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research report on Monday, July 2nd. Morgan Stanley raised their price objective on Diplomat Pharmacy from $16.00 to $21.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 3rd. Leerink Swann reaffirmed an “outperform” rating and issued a $33.00 price objective on shares of Diplomat Pharmacy in a research report on Friday, June 22nd. Finally, JPMorgan Chase & Co. raised Diplomat Pharmacy from a “neutral” rating to an “overweight” rating in a research report on Thursday, May 10th. Eight investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $26.64.
Get Diplomat Pharmacy alerts:The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of 25.38 and a beta of 1.33. The company has a quick ratio of 0.57, a current ratio of 0.88 and a debt-to-equity ratio of 0.59.
Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings results on Monday, May 7th. The company reported $0.20 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.21 by ($0.01). The firm had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.28 billion. Diplomat Pharmacy had a return on equity of 8.80% and a net margin of 0.23%. The business’s revenue for the quarter was up 24.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.19 earnings per share. equities research analysts anticipate that Diplomat Pharmacy Inc will post 0.92 EPS for the current year.
In related news, Director Shawn Tomasello sold 1,680 shares of Diplomat Pharmacy stock in a transaction that occurred on Tuesday, June 5th. The stock was sold at an average price of $24.27, for a total transaction of $40,773.60. Following the completion of the sale, the director now directly owns 12,816 shares of the company’s stock, valued at approximately $311,044.32. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Jeffrey G. Park sold 1,695 shares of Diplomat Pharmacy stock in a transaction that occurred on Monday, June 11th. The stock was sold at an average price of $25.26, for a total value of $42,815.70. The disclosure for this sale can be found here. Over the last three months, insiders have sold 17,250 shares of company stock valued at $419,364. 24.70% of the stock is currently owned by insiders.
A number of large investors have recently added to or reduced their stakes in the stock. Frontier Capital Management Co. LLC lifted its holdings in Diplomat Pharmacy by 2.5% during the 1st quarter. Frontier Capital Management Co. LLC now owns 3,919,051 shares of the company’s stock worth $78,969,000 after purchasing an additional 94,861 shares during the last quarter. GW&K Investment Management LLC lifted its holdings in Diplomat Pharmacy by 1.9% during the 1st quarter. GW&K Investment Management LLC now owns 1,024,336 shares of the company’s stock worth $20,640,000 after purchasing an additional 19,222 shares during the last quarter. Point72 Asset Management L.P. lifted its holdings in Diplomat Pharmacy by 1,424.3% during the 1st quarter. Point72 Asset Management L.P. now owns 939,562 shares of the company’s stock worth $18,932,000 after purchasing an additional 877,922 shares during the last quarter. Redwood Investments LLC bought a new position in Diplomat Pharmacy during the 1st quarter worth $16,716,000. Finally, Matarin Capital Management LLC bought a new position in Diplomat Pharmacy during the 1st quarter worth $12,790,000. 74.85% of the stock is owned by institutional investors and hedge funds.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
See Also: What does RSI mean?
Small and underpowered in its day, the Subaru 360 feels even more out of place on modern roads.
Even by the standards of cheap cars, the Subaru 360 was spartan.